387 related articles for article (PubMed ID: 10343018)
21. Ripe for revision: reassessing the constitutionality of Food and Drug Administration restrictions on protected speech.
Gibbs JN; Ferrari PL; Murphy AM;
Food Drug Law J; 2003; 58(3):331-45. PubMed ID: 14626233
[No Abstract] [Full Text] [Related]
22. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
Anthony M; Romero K; Malone DC; Hines LE; Higgins L; Woosley RL
Clin Pharmacol Ther; 2009 Oct; 86(4):425-9. PubMed ID: 19587643
[TBL] [Abstract][Full Text] [Related]
23. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
24. Lessons from cisapride.
CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
[No Abstract] [Full Text] [Related]
25. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
Kuhlik BN
Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
[No Abstract] [Full Text] [Related]
26. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.
Hayes TA
Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174
[No Abstract] [Full Text] [Related]
27. Surfing the Net in shallow waters: product liability concerns and advertising on the Internet.
Moberg MA; Wood JW; Dorfman HL
Food Drug Law J; 1998; 53(2):213-24. PubMed ID: 10346682
[No Abstract] [Full Text] [Related]
28. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
30. The new drug marketing: a consumer protection perspective.
Woodward D
Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
[No Abstract] [Full Text] [Related]
31. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
Helmanis AM
Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
[No Abstract] [Full Text] [Related]
32. MedGuide: at last a long-sought opportunity for patient education about prescription drugs.
Marwick C
JAMA; 1997 Mar; 277(12):949-50. PubMed ID: 9091654
[No Abstract] [Full Text] [Related]
33. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
Reichertz PS
Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
[No Abstract] [Full Text] [Related]
34. Changes at FDA may speed drug approval process and increase off-label use.
Reh M
J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166
[No Abstract] [Full Text] [Related]
35. [Can we rely on drug information?].
Myhr K
Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2644-6. PubMed ID: 12523198
[No Abstract] [Full Text] [Related]
36. FDA proposes mechanism for disseminating information about off-label uses.
Am J Health Syst Pharm; 1998 Jul; 55(14):1449-50. PubMed ID: 9676288
[No Abstract] [Full Text] [Related]
37. Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
Reichertz PS
Food Drug Law J; 1996; 51(3):355-65. PubMed ID: 11797712
[No Abstract] [Full Text] [Related]
38. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
39. Inappropriate advertising of dietary supplements.
Taylor H
N Engl J Med; 2003 May; 348(22):2255-6; author reply 2255-6. PubMed ID: 12773657
[No Abstract] [Full Text] [Related]
40. A global view of the First Amendment constraints of FDA.
Carver KH
Food Drug Law J; 2008; 63(1):151-215. PubMed ID: 18561459
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
